ALX ONCOLOGY HOLDINGS INC (ALXO)
Health Care · Immuno-oncology / checkpoint inhibitors · NASDAQ
An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer therapies.
What ALX ONCOLOGY HOLDINGS INC does
ALX Oncology is a clinical-stage biotechnology company developing novel immuno-oncology therapies to treat cancer. The company's lead candidate is evorpacept (ALX 148), a next-generation CD47 blocker designed to enhance macrophage-mediated tumor cell killing when combined with other anti-cancer agents. Its second pipeline candidate is ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) that entered Phase 1 trials in 2025. The company has no approved products or product revenue to date.
Themes: CD47 checkpoint inhibitors / macrophage activation, Immuno-oncology, Cancer immunotherapy combinations, HER2-positive breast cancer, Gastric/esophageal junction cancer, EGFR-targeted therapies
Fundamentals
- Price$1.99 as of 2026-08-24 close
- Market cap$275M as of 2026-08-24
- 1-year return+70.1% 2025-08-22 close $1.17 → 2026-08-24 close $1.99
- P/En/a negative earnings
- Net margin-753.5% as of 2026-08-24
- Gross margin+9.0% as of 2026-08-24
- ROE-124.1% as of 2026-08-24
- Debt / equity0.07 as of 2026-08-24
- Beta0.98 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ALXO compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALX ONCOLOGY HOLDINGS INC looks technically
ALX ONCOLOGY HOLDINGS INC (ALXO) is trading 11.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 9, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 35 trading days ago. It is 25.2% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 28% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 11.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.96 | $1.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.79 | $1.79 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.18. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal | 225 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 9, below the 25 that marks a real trend) | 8.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.87 to $2.18) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 38.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.66 | $2.66 |
|---|---|---|
| From the 52-week high | it is 25.2% below its 52-week high (its highest price of the past year) | -25.2% |
| Above the 52-week low | it is 150.0% above its 52-week low (its lowest price of the past year) | +150.0% |
| Below the 52-week high | it is 25.2% below its highest point of the past year | 25.2% |
| Since a 20-day breakout | it made a new 20-day high about 35 trading days ago | 35 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $88.46 (set on 2021-03-01) | $88.46 |
| Given back of the 52-week move | over the past year its closes ranged ($0.832 to $2.60), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.45 to $1.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.5% |
| From the all-time high | it is 97.8% below its all-time high | -97.8% |
| Nearest price level | it is trading 2.0% above a support level at $1.95 — a price it turned at twice since 2025-01-08, most recently on 2026-03-13. Since 2024-08-26 it has 12 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.0% |
| All-time low | its lowest closing price on record is $0.404 (set on 2025-06-27) | $0.404 |
| Above the all-time low | it is 392.6% above its all-time low | +392.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move | 4th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1268 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1268 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.88 and $2.11 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.88 – $1.99 – $2.11 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (11.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 28% of its 30-day average | 0.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-24 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.0% |
|---|---|---|
| Gap filled | a 3.5% gap up opened on 2026-07-28 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.3 percentage points (the stock lost 2.0% while the market gained 3.3%) | -5.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.9 percentage points (the stock gained 0.5% while the market gained 2.4%) | -1.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 29.8 percentage points (the stock lost 18.8% while the market gained 11.1%) | -29.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 51.8 percentage points (the stock gained 70.1% while the market gained 18.3%) | +51.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 6.7% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.94 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +2.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.05 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
ALXO last closed at $1.99 on 2026-08-24. Since 2024-08-26 it has turned at 12 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.95 | Support | 2.0% below the last close | turned there twice · 2025-01-08 to 2026-03-13 |
| $1.90 | Support | 4.5% below the last close | turned there twice · 2025-10-24 to 2026-07-16 |
| $1.86 | Support | 6.4% below the last close | turned there three times · 2024-12-05 to 2026-07-31 |
| $2.18 | Resistance | 9.7% above the last close | turned there twice · 2026-05-12 to 2026-08-07 |
| $2.27 | Resistance | 13.8% above the last close | turned there twice · 2025-10-06 to 2026-03-20 |
| $2.36 | Resistance | 18.6% above the last close | turned there twice · 2024-09-16 to 2026-03-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.18.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$4.60 range $4.00 – $6.00; median $4.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALXO
- Consensus EPS estimate-$0.1638 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company has never generated product revenue and expects significant net losses for the foreseeable future; substantial additional capital will be required to continue operations","Lead candidate evorpacept has not completed a pivotal trial; clinical development is expensive, lengthy, and unpredictable with no guarantee of regulatory approval or commercial success","High dependence on key personnel and third-party manufacturers for clinical supplies; relies on patent protection in a competitive immuno-oncology landscape"]
What changed in the latest 10-Q
AI-assisted comparison of ALXO's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) specifies evorpacept clinical trial as 'ASPEN-09-Breast' instead of 'ASPEN-Breast'
- Newer filing adds detail that ASPEN-06 data 'was previously presented' and results 'were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting' (past tense, November 2025)
- Newer filing adds expanded description of evorpacept combination trials: mentions phase 1/2 IST 'and subsequently, in patients with newly diagnosed indolent B-cell NHL' and adds 'phase 1b/2 trial of evorpacept with zanidatamab in patients with HER2-positive breast cancer'
- Newer filing changes OS hazard ratio from 0.63 to 0.70 in ASPEN-06 gastric cancer analysis
- Newer filing changes median PFS language from 'PFS of 18.4 months' to 'median PFS (mPFS) of 18.4 months'
- Newer filing changes median OS language from 'OS of 17 months' to 'median OS (mOS) of 17 months'
- Removed:
- Older filing (2025-11-07) described evorpacept as 'Our lead product' whereas newer filing uses 'Our lead product candidate'
- Older filing text 'will be highlighted as part of a poster presentation at the SITC Annual Meeting on November 8th' removed; replaced with past-tense 'was highlighted as part of a poster presentation at the SITC Annual Meeting in November 2025'
- Older filing reference to 'recent clinical data of our investigator-sponsored trial (IST) collaborator from the ongoing Phase 1/2 IST' language simplified in newer filing
- Older filing describes ALX2004 created from 'proprietary linker-payload platform' changed to 'proprietary linker-payload library' in newer filing
- Older filing lists 'the CD38-targeted antibody isatuximab-irfc' omitted from newer filing's list of antibodies evorpacept combined with
- Reworded:
- Older: 'Our lead product, evorpacept' changed to newer: 'Our lead product candidate, evorpacept'
- Older: 'ASPEN-06 evaluates' (present tense) changed to newer: 'ASPEN-06 evaluated' (past tense)
- Older: 'Results from a pre-planned exploratory analysis will be presented' changed to newer: 'Results from a pre-planned exploratory analysis were presented'
- Older: 'The data will be highlighted as part of a poster presentation at the SITC Annual Meeting on November 8th' changed to newer: 'The data was highlighted as part of a poster presentation at the SITC Annual Meeting in November 2025'
- Older: 'Evorpacept has been combined in clinical trials with multiple anti-cancer antibodies in addition to trastuzumab' changed to newer to add specific reference to 'the CD20-targeted antibody rituximab, the CD38-targeted antibody isatuximab-irfc, and the HER2-targeted bispecific antibody zanidatamab' before discussing trials
- Older: 'and the recent clinical data of our investigator-sponsored trial (IST) collaborator from the ongoing Phase 1/2 IST' changed to newer: 'the Phase 1/2 investigator-sponsored trial (IST) of evorpacept in combination with rituximab and lenalidomide in patients with relapsed refractory B-cell NHL (R/R B-NHL) and subsequently, in patients with newly diagnosed indolent B-cell NHL'
- Older: 'ASPEN-Breast - Breast Cancer' changed to newer: 'ASPEN-09-Breast – HER2+ Breast Cancer'
- Older: 'proprietary linker-payload platform' changed to newer: 'proprietary linker-payload library'
- Older: 'engineered for optimal activity as an antibody drug conjugate (ADC)' changed to newer: 'engineered for optimal activity as an ADC'
- Notes:
- Both filings appear to be quarterly reports for different periods (Q2 2026 vs Q3 2025); comparison spans approximately 6 months of corporate updates
- The newer filing's MD&A section is truncated mid-sentence at 'In March 2025, we announced intent to initiate a randomized Phase', preventing full comparison of subsequent clinical program details
- OS hazard ratio change (0.63 to 0.70) is a factual discrepancy that warrants verification against source data
Risk Factors
- Added:
- Reference to ALX2004 in the context of seeking marketing approval (newer filing, 2026-05-08)
- Updated net loss figure of $17.9 million for three months ended March 31, 2026 (newer filing, 2026-05-08)
- Updated accumulated deficit of $740.7 million as of March 31, 2026 (newer filing, 2026-05-08)
- Removed:
- Reference to 'duration of the U.S. federal government shutdown' (present in older filing, 2025-11-07)
- Reference to past identification of material weaknesses in internal control over financial reporting (present in older filing, 2025-11-07)
- Net loss figure of $22.1 million for three months ended September 30, 2025 (older filing, 2025-11-07)
- Net loss figure of $30.7 million for three months ended September 30, 2024 (older filing, 2025-11-07)
- Accumulated deficit of $700.0 million as of September 30, 2025 (older filing, 2025-11-07)
- Reference to 'advance our other programs' without mention of ALX2004 (older filing, 2025-11-07)
- Reworded:
- Page number changed from 35 to 33 (newer filing, 2026-05-08)
- Internal control risk factor changed from 'In the past, we have identified material weaknesses...' to 'If we are unable to implement and maintain effective internal control...' (newer filing, 2026-05-08)
- Macroeconomic risk factor: 'duration of the U.S. federal government shutdown' changed to 'U.S. federal government shutdowns' (newer filing, 2026-05-08)
- Clinical trial reference expanded from 'conduct clinical trials of, and seek marketing approval for evorpacept and advance our other programs' to 'conduct clinical trials of, and seek marketing approval for evorpacept and ALX2004 and advance our other programs' (newer filing, 2026-05-08)
- Notes:
- The newer filing text appears truncated at the end; comparison limited to complete sections visible
- Numerical updates (net losses, accumulated deficit) reflect different reporting periods (Q2 2026 vs Q3 2025)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($5410) — 2 selling insiders
- Last 90 days0 buys · 3 sells ($8274) — 2 selling insiders
- Last 180 days0 buys · 5 sells ($36948) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-17. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALXO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALXO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,406,212
- Reported value $2,819,454
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ALXO had 7,718,258 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ALXO had 5.58% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.28 days to cover at the same settlement.
- Reported short interest (shares) 7,718,258
- Short interest (% of shares outstanding) 5.58%
- Prior settlement (shares) 7,460,211
- Reported change 3.46%
- Days to cover (reported) 13.28
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- AbbVie (ABBV)
- Pfizer (PFE)
- Bristol Myers Squibb (BMY)
- Seagen (acquired by Pfizer)
- MacroGenics (MGNX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALXO vs…
ALX ONCOLOGY HOLDINGS INC is found in…
Frequently asked questions
What does ALX ONCOLOGY HOLDINGS INC (ALXO) do?
ALX Oncology is a clinical-stage biotechnology company developing novel immuno-oncology therapies to treat cancer. The company's lead candidate is evorpacept (ALX 148), a next-generation CD47 blocker designed to enhance macrophage-mediated tumor cell killing when combined with other anti-cancer agents. Its second pipeline candidate is ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) that entered Phase 1 trials in 2025. The company has no approved products or product revenue to date.
What sector is ALX ONCOLOGY HOLDINGS INC (ALXO) in?
ALX ONCOLOGY HOLDINGS INC (ALXO) is classified in the Health Care sector. Its industry is Immuno-oncology / checkpoint inhibitors. It trades on NASDAQ.
Who are ALX ONCOLOGY HOLDINGS INC's (ALXO) competitors?
Notable peers of ALX ONCOLOGY HOLDINGS INC (ALXO) include Gilead Sciences, AbbVie, Pfizer, Bristol Myers Squibb and Seagen (acquired by Pfizer). This peer set is informational only — not financial advice.
Is ALX ONCOLOGY HOLDINGS INC (ALXO) overbought or oversold right now?
ALX ONCOLOGY HOLDINGS INC (ALXO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALXO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.